

## Commercial Contract for Breast Cancer Risk Study with University of Melbourne

### Key Highlights

- ✓ Rhythm subsidiary, Genetype secures a 12-month contract to provide geneType™ Breast Cancer Risk assessment to the University of Melbourne;
- ✓ Study is designed to provide improved Breast Cancer Risk Screening services; and
- ✓ Accelerates and diversifies the Genetype business commercial growth profile.

**Melbourne, Australia, 15 May 2025:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, today releases a business update in relation to further commercial success in its Genetype subsidiary.



The integration of the Genetype business into Rhythm is focussed on building processes that could be significantly scaled compared to how the processes were configured previously. This preparation for success is catering for an accelerated growth profile from commercial and public clinical services as well as from academic partnerships. This commercial partnership with the University of Melbourne is an excellent example of a clinical research group progressing clinical implementation studies to support wide-spread utility of personalised risk-based approach to screening.

The study conducted by the University of Melbourne aims to improve breast cancer screening for Australian women aged 40-59 by introducing a personalised risk assessment approach that supports current national guidelines provided by The Royal Australian College of General Practitioners (RACGP). This innovative methodology incorporates major risk factors such as family history, mammographic breast density (MBD) and a polygenic risk score (PRS). The study also addresses the financial aspect by covering the costs of any additional imaging required as a result of identified risks, ensuring participants can access vital follow-up care without financial burden (incorporating a Medicare Benefits Schedule (MBS) Item number for women who qualify for supplemental MRI screening based on risk).

Acceptability measures will evaluate attitudes and willingness to engage in this risk-stratified screening, while qualitative interviews will provide insights into participants' understanding and acceptance of the intervention that will personalise screening recommendations according to their risk.

Ultimately, this study not only explores the feasibility of implementing risk-stratified breast cancer screening but also aims to lay the groundwork to justify incorporation of superior risk models, such as geneType™ into population screening programs.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

#### Directors

Otto Buttula  
Sue MacLeman  
Gavin Fox-Smith  
David Atkins

Non-Executive Chairman  
Non-Executive Director  
Non-Executive Director  
CEO & Managing Director

[www.rhythmbio.com](http://www.rhythmbio.com)

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

**Rhythm Biosciences Director of Clinical & Scientific Affairs, Dr Erika Spaeth commented;**

*“We are delighted to announce the commencement of the Robin study that will support implementation of polygenic-integrated risk assessment in a breast centre setting. We are honoured to work with the team led by Professor Jon Emery and the late Professor John Hopper on this study. This continues to strengthen the business case supporting the Genetype acquisition. Real-world implementation and feasibility data of our risk stratification tool in the Australian breast screen environment is an exciting step forward in expanding a robust portfolio of evidence supporting the use of risk-stratified screening approaches as a potentially enhanced standard-of-care.”*

**Professor Jon Emery commented;**

*“We are delighted to be working with Rhythm Biosciences on this first ever study to examine the feasibility and acceptability of using a risk model that includes mammographic density and polygenic risk to tailor breast cancer screening in Australia. Ultimately, we aim to improve the effectiveness of breast cancer screening by providing more targeted approaches based on a woman's breast cancer risk.”*

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

**About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

**About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).